Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2015-04-15 Annual Report
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Annual Report 2014
Annual Report Classification · 100% confidence The document is a comprehensive annual report for the company Sobi for the year 2014. It contains detailed business highlights, a CEO statement, financial summaries, key figures, and references to the Directors' Report and audited financial statements. It is clearly a full-year report covering company activity and financial performance, fitting the definition of a 10-K (Annual Report). FY 2014
2015-04-15 English
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)" and details the date, location, procedures for participation, and the proposed agenda for the meeting. The agenda items cover standard AGM topics like election of the chairman, approval of financial statements, discharge of directors, determination of fees, and election of the board/auditor. This content directly corresponds to the materials distributed for an Annual General Meeting. Therefore, the classification is AGM-R.
2015-03-30 English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ)" which translates to 'Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)'. It details the date, time, location, registration procedures, proposed agenda items (including election of board members, approval of remuneration, and incentive programs), and specific proposals related to the AGM. This content is characteristic of a formal notice and agenda for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length is substantial (over 40k characters), confirming it is the primary document, not just an announcement of the meeting.
2015-03-30 Swedish
Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix® paediatric study
Earnings Release Classification · 98% confidence The document is explicitly titled '# **PRESS RELEASE**' and announces 'positive top-line efficacy and safety results' from a Phase 3 clinical study (Kids B-LONG) for a drug (Alprolix). It details study endpoints, safety profiles, and future regulatory plans (supporting EU Regulatory Submission). This structure—a concise announcement of key financial or operational results, often released before a full report—is characteristic of an Earnings Release (ER). While it discusses clinical data, its primary function here is to communicate recent operational success/milestones to the market immediately, fitting the ER definition better than a comprehensive Interim Report (IR) or a standalone Audit Report (AR). It is not a transcript (CT), a management discussion (MDA), or a formal regulatory filing like a 10-K. FY 2015
2015-02-27 English
Biogen Idec och Sobi meddelar positiva effekt- och säkerhetsresultat från företagens fas-3-studie på barn av läkemedelskandidaten Alprolix® (rFIXFc) för hemofili B
Regulatory Filings Classification · 90% confidence The document is a press release (indicated by "# **PRESSMEDDELANDE**") announcing positive efficacy and safety results from a Phase 3 clinical trial (Kids B-LONG) for a drug candidate (Alprolix) used to treat Hemophilia B. It details study endpoints, patient outcomes (bleeding rates, inhibitor development), and the implications for regulatory submissions (EMA, FDA). This content is characteristic of an announcement detailing clinical trial progress and its impact on future regulatory steps, which falls under the scope of general corporate or scientific news releases. Since it is not a full Annual Report (10-K), a formal Audit Report (AR), a specific financing update (CAP), or a formal Earnings Release (ER) focusing purely on financial metrics, the most appropriate classification is a general Regulatory Filing (RNS) as a broad category for significant corporate announcements that don't fit elsewhere, or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release detailing study results, RNS is the best fit among the provided options, as it is a significant public disclosure. However, given the focus on clinical trial results and the implication for market authorization, it is a scientific/clinical update. None of the categories perfectly capture 'Clinical Trial Results Announcement'. Comparing the options, it is not a formal financial report (10-K, IR, ER, MRQ). It is a public announcement. RNS is the fallback for general regulatory announcements. Since it is a press release announcing scientific data, RNS is the most suitable general disclosure category.
2015-02-27 Swedish
Sobi publicerar sin rapport för fjärde kvartalet och bokslutskommuniké för 2014
Audit Report / Information Classification · 95% confidence The document is titled "Bokslutskommuniké 2014" (Year-end report/Financial Statement Release 2014) and contains detailed financial tables for Q4 and the full year 2014, including income statements, key figures, and management commentary ("VD har ordet"). This structure strongly indicates a comprehensive report covering a full fiscal year's performance. While it contains elements of an Earnings Release (ER) by summarizing Q4 results, its depth, inclusion of full-year figures, and the nature of a 'Bokslutskommuniké' (which often serves as the basis for the official Annual Report or a detailed interim report) points towards a comprehensive financial report. Since it covers the full year and is highly detailed, it aligns best with the definition of an Annual Report (10-K) or a comprehensive Interim Report (IR). Given the context of a year-end communication providing full financial details, and lacking the explicit '10-K' header, it is classified as a comprehensive report. In many jurisdictions, the year-end financial statement release serves the function of the Annual Report. However, since the provided definitions separate 10-K (Official yearly report) from IR (Comprehensive report for a period shorter than a year), and this covers the full year, 10-K is the closest fit for a comprehensive annual financial disclosure, even if it's a local equivalent. If it were purely an initial press release of results, ER would be appropriate, but the detail suggests more. Given the comprehensive nature covering the entire fiscal year, 10-K is the most appropriate classification among the choices for a full-year financial disclosure. FY 2014
2015-02-19 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.